biotech · Melanoma · Previously untreated, unresectable, or metastatic melanoma · IOBTQ
IO Biotech
IO Biotech is a biotech organization headquartered in copenhagen, DK. It trades on NYSE under ticker IOBTQ. Primary therapeutic focus areas include Melanoma, Previously untreated, unresectable, or metastatic melanoma, ad
Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK HQ
2015 Founded
50 Employees
Public company Type
IOBTQ · NYSE Ticker
Company details
- Status
- Public
- HQ
- Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK
- Founded
- 2015
- Employees
- 50
- Programs
- 16
- Drugs
- 8
- Patents
- 21
IO102-IO103 in combination with pembrolizumab
Phase 2 · small molecule · Lung Cancer Non Small Cell
IO102-IO103 in combination with pembrolizumab for Lung Cancer Non Small Cell is a Phase 2 program (small_molecule) at IO Biotech with 1 ClinicalTrials.gov record(s).
Internal code IOB-022
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- IO Biotech
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Lung Cancer Non Small Cell
- Status
- completed
- Trials
- 1